Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H29FN3O9P |
Molecular Weight | 529.4525 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC3=CC=CC=C3
InChI
InChIKey=TTZHDVOVKQGIBA-IQWMDFIBSA-N
InChI=1S/C22H29FN3O9P/c1-13(2)33-19(29)14(3)25-36(31,35-15-8-6-5-7-9-15)32-12-16-18(28)22(4,23)20(34-16)26-11-10-17(27)24-21(26)30/h5-11,13-14,16,18,20,28H,12H2,1-4H3,(H,25,31)(H,24,27,30)/t14-,16+,18+,20+,22+,36-/m0/s1
Molecular Formula | C22H29FN3O9P |
Molecular Weight | 529.4525 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 6 / 6 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
Approval Year
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 20:27:35 UTC 2023
by
admin
on
Fri Dec 15 20:27:35 UTC 2023
|
Record UNII |
WJ6CA3ZU8B
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J05AP55
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
NCI_THESAURUS |
C281
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
WHO-ATC |
J05AX65
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
WHO-ATC |
J05AX15
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
FDA ORPHAN DRUG |
535916
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
WHO-ATC |
J05AP08
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
SOVALDI (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
NDF-RT |
N0000191493
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
NCI_THESAURUS |
C25995
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
FDA ORPHAN DRUG |
541716
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
WHO-ATC |
J05AP51
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
FDA ORPHAN DRUG |
554816
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
EMA ASSESSMENT REPORTS |
HARVONI (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
||
|
WHO-ATC |
J05AP56
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
DTXSID701027632
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
7368
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
8226
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
m11680
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
WJ6CA3ZU8B
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
100000144530
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
SOFOSBUVIR
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
C101263
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
9665
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
DB08934
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
85083
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
1190307-88-0
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
N0000191258
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | RNA Replicase Inhibitors [MoA] | ||
|
1484911
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | RxNorm | ||
|
WJ6CA3ZU8B
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
CHEMBL1259059
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
4811
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
45375808
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
Sofosbuvir
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
SUB121170
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY | |||
|
XX-67
Created by
admin on Fri Dec 15 20:27:36 UTC 2023 , Edited by admin on Fri Dec 15 20:27:36 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TARGET -> INHIBITOR | |||
|
EPIMER -> DIASTEREOISOMER | |||
|
EXCRETED UNCHANGED |
URINE
|
||
|
TARGET ORGANISM->INHIBITOR |
|
||
|
EXCRETED UNCHANGED |
URINE
|
||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE INACTIVE -> PARENT | |||
|
METABOLITE ACTIVE -> PRODRUG |
MINOR
|
||
|
METABOLITE -> PARENT |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
ORAL ADMINISTRATION |
|
||